AbbVie (ABBV) Return on Capital Employed (2013 - 2026)

AbbVie (ABBV) has 14 years of Return on Capital Employed data on file, last reported at 16.47% in Q1 2026.

• Return on Capital Employed for Q1 2026 came in at 16.47%, up 632.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 16.47% (up 632.0% YoY), and the FY2025 annual result was 16.52%, up 702.0% from the prior year.
• Return on Capital Employed retreated to 16.47% in Q1 2026 per ABBV's latest filing, from 16.63% in the prior quarter.
• Over five years, Return on Capital Employed peaked at 16.93% in Q2 2023 and troughed at 9.09% in Q4 2024.
• A 5-year average of 13.9% and a median of 14.82% in 2023 frame the typical range for Return on Capital Employed.
• The sharpest annual moves came in 2024 and 2025: Return on Capital Employed tumbled 507 bps in 2024, then jumped 754 bps in 2025.
• A 5-year view of Return on Capital Employed shows it stood at 16.39% in 2022, then dropped by 20 bps to 13.07% in 2023, then tumbled by 30 bps to 9.09% in 2024, then jumped by 83 bps to 16.63% in 2025, then declined by 1 bps to 16.47% in 2026.
• Business Quant data shows ABBV's Return on Capital Employed at 16.47% in Q1 2026, 16.63% in Q4 2025, and 9.4% in Q3 2025.